Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|25/02/2020||Appendix 4D & Half-Year Financial Statements||Download|
|20/02/2020||Race significantly strengthens Clinical Advisory Board||Download|
|17/02/2020||Race appoints Australian Clinical Program Director||Download|
|03/02/2020||Appendix 3X-Prof Borje Andersson||Download|
|30/01/2020||December 2019 Quarterly Report||Download|
|28/01/2020||Prof Borje Andersson appointed as Non-Executive Director||Download|
|14/01/2020||Notification of Expiry of Unlisted Options||Download|